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Abstract
Rotavirus (RV) is the main cause of acute gastroenteritis (AGE) in young children. The San
Luis province of Argentina introduced RV vaccination in May 2013. We estimate vaccine
impact (RVI) using real-world data. Data on all-cause AGE cases and AGE-related hospita-
lisations for San Luis and the adjacent Mendoza province (control group) were obtained
and analysed by interrupted time-series methods. Regardless of the model used for counter-
factual predictions, we estimated a reduction in the number of all-cause AGE cases of 20–25%
and a reduction in AGE-related hospitalisations of 55–60%. The vaccine impact was similar
for each age group considered (<1 year, <2 years and <5 years). RV vaccination was estimated
to have reduced direct medical costs in the province by about 4.5 million pesos from May 2013
to December 2014. Similar to previous studies, we found a higher impact of RV vaccination in
preventing severe all-cause AGE cases requiring hospitalisation than in preventing all-cases
AGE cases presenting for medical care. An assessment of the economic value of RV vaccin-
ation could take other benefits into account in addition to the avoided medical costs and the
costs of vaccination.
Introduction
Rotavirus (RV) infection is the main cause of severe diarrhea and acute gastroenteritis (AGE)
in infants and young children, while diarrhea is the second most frequent cause of childhood
death [1]. Across the world, virtually all children will have been infected with RV before the
age of 5 years and suffered an RV gastroenteritis (RVGE) with diarrhea, vomiting and other
symptoms like nausea and stomach cramps. RV is transmitted primarily via the faecal-oral
route and transmission occurs either directly between persons or via touching contaminated
surfaces, where the virus may remain infectious for extended periods [2, 3].
Effective, live-attenuated RV vaccines have been available and licensed since 2006; in 2009,
the WHO recommended implementation of RV vaccination in the routine childhood vaccin-
ation programs in all countries, and in priority in countries with high AGE-related childhood
mortality [4].
Most Latin American countries were among the early adopters of this policy recommended
by the WHO. Some countries in the continent, Chile, Uruguay and Argentina among them,
with very low-diarrhea-associated childhood mortality rates did not at first adopt RV vaccin-
ation widely. However, these countries allowed primary-care physicians to administer RV vac-
cination on an individual basis [5]. Contrary to Chile and Uruguay where population-wide RV
vaccination has not yet been introduced, Argentina included this in its national routine child-
hood vaccination program in January 2015 [6]. Like all the vaccines in the program, RV vac-
cination is provided at zero out-of-pocket costs for all children.
The clinical care and possible treatment of AGE cases do not depend on the specific causa-
tive agent so the common practice is that laboratory testing of biological specimens is relatively
uncommon, particularly in cases presented in primary care. Studies in Argentina found that
16.8% of AGE cases treated in outpatient settings [7] and 42% of hospitalised AGE cases
were RVGE [8].
A single Argentinian province, San Luis, included RV vaccination in its routine childhood
vaccination program in May 2013, almost 2 years earlier than the national one. This diver-
gence in the time of introduction presents an excellent and relatively rare opportunity for
using a quasi-experimental design to evaluate the early impact of RV vaccination in ordinary
clinical practice.
We performed an impact study at the population level aiming at measuring the early
impact of RV vaccination by using health outcomes data pre- vs. post-introduction of the
RV vaccine. The impact of RV vaccination is estimated by comparing the observed health
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outcomes in San Luis province post RV vaccine introduction with
a counterfactual prediction of what the outcomes would have
been without the vaccine.
Methods and material
The study period extended from 1 January 2008 to 31 December
2016. The RV vaccination was introduced in San Luis in May
2013, so the pre-vaccination period ended on 30 April 2013, at
which date the post-vaccination period began. No transition per-
iod was considered. A full 2-dose vaccination schedule must be
completed before the infant is 24 weeks old.
AGE is a mandatory notifiable disease in Argentina, which is
to be reported to the National Health Surveillance System
(SNVS). A clinical module of SNVS is used to collect information
from all ‘medical consultations’ regardless of the setting in which
they take place (primary care, ambulatory services, emergency
rooms and hospital units). Another module collects information
from laboratory surveillance based on the biological specimens
received and analysed by SNVS laboratory networks. The clinical
module SNVS data was used to estimate the incidence of all-cause
AGE at the provincial level in children aged <5 years.
The data on all-cause AGE-associated hospitalisations were
derived from hospital discharge (HD) data from the Public
Health Sector at the provincial level. Admissions with the dis-
charge diagnoses ‘intestinal infection due to a virus and other spe-
cified organisms’ or ‘diarrhea and gastroenteritis of presumed
infectious origin’ (CIE-10) were considered as AGE-associated
and included in the study. Only one AGE-related death occurred
during the study period, so this outcome was not analysed.
No major changes in the methods for registering AGE cases,
hospitalisations or in the health care system of any of the two pro-
vinces were identified as occurring during the study period. It was
therefore assumed that the difference between the observed and
predicted incidence of AGE and the number of AGE-associated
hospitalisations could be attributed to RV vaccination. The
robustness of this assumption was assessed by repeating the stat-
istical analyses with randomly selected five hypothetical time
points for the RV vaccine introduction. The assumption would
be considered robust if these analyses with hypothetical time
points for the intervention showed no effect in any of them.
Only when the actual date of vaccine introduction was consid-
ered in the model could we identify an effect in terms of reduc-
tions in AGE cases and hospitalisations in the analysis.
An estimate of the direct healthcare costs avoided due to the
impact of RV vaccination was derived based on unit cost estimates
for outpatient care and hospitalisations from an economic evalu-
ation of RV vaccine published in 2011 [9]. The cost estimates were
updated to 2014 values by using inflation data from the general
Provincial Bureau of Statistics and Census in San Luis.
After the introduction of the RV vaccination in May 2013, a
coverage rate for the 2-dose schedule of 99% was achieved already
in 2014 and more or less maintained throughout the study period,
so full coverage was assumed.
Fig. 1. Number of AGE cases for different age groups per 4-week periods for San Luis. AGE, acute gastroenteritis.
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Statistical analyses
The data were analysed by interrupted time-series methods with
the aim of predicting what the outcomes would have been in
San Luis, if the RV vaccination had not been introduced. The spe-
cific model used was an indirect, counterfactual Bayesian predic-
tion [10], a method that generalises the widely used
difference-in-differences approach to time-series analyses by
explicitly modelling the counterfactual of a time series observed
both before and after an intervention. It improves on existing
methods in two aspects: it provides a fully Bayesian time-series
estimate for the effect; and it uses model averaging to construct
the most appropriate synthetic control for modelling the
counterfactual. This powerful approach to constructing the coun-
terfactual is based on the idea of combining a set of candidate pre-
dictor variables into a single ‘synthetic control’ [11, 12]. There are
three sources of information available for constructing an
adequate synthetic control. The first is the time-series behaviour
of the outcome prior to the intervention. The second is the behav-
iour of other time series that were predictive of the outcome series
prior to the intervention. In a Bayesian framework, a third source
of information for inferring the counterfactual is the available
prior knowledge about the model parameters, for example as eli-
cited by previous studies.
We combine these sources of information using a state-space
time-series model, where one component of state is a linear
Fig. 2. Boxplot of the distribution of the number
of AGE cases per 4-week period each year of the
study period in children in different age groups
in San Luis. AGE, acute gastroenteritis.
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regression on the contemporaneous predictors. The framework of
our model allows us to choose from among a large set of potential
controls by placing a spike-and-slab prior to the set of regression
coefficients and by allowing the model to average over the set of
controls [13]. We then compute the posterior distribution of the
counterfactual time series given the value of the outcome series in
the pre-intervention period, along with the values of the controls
in the post-intervention period. Subtracting the predicted from
the observed outcome during the post-intervention period gives
a semiparametric Bayesian posterior distribution for the causal
effect.
San Luis data from January 2008 to the end of April 2013 were
used to model the counterfactual prediction of the number of
AGE cases and related hospitalisations that would have occurred
from May 2013 until the end of 2016 regarding AGE cases and
until the end of 2015 regarding hospitalisations if the RV vaccin-
ation had not been introduced.
In addition, data from the Mendoza province, which did not
introduce RV vaccination until January 2015, were used as a con-
trol and San Luis AGE events were adjusted using these data. The
Mendoza province is adjacent to San Luis with similar weather,
geography and sanitation conditions and prior to the introduction
of RV vaccination in San Luis, the incidences of all AGE cases and
AGE-associated hospitalisations were equivalent in both pro-
vinces. As RV vaccination was introduced in Mendoza in
January 2015, concurrently with its introduction in the National
Immunisation Program, this model with Mendoza data as a con-
trol group was used to estimate the impact of RV vaccination in
San Luis until the end of 2014. This prediction model assumes
that the relationship between the outcomes observed in San
Luis and Mendoza prior to the start of RV vaccination in May
2013 would have remained stable in the prediction period, if vac-
cination had not been introduced.
The predicted number of AGE cases and AGE-related hospita-
lisations, the average number of cases and hospitalisations averted
per time period, the relative effect of RV vaccination and the
cumulative number of cases and hospitalisations averted were esti-
mated with 95% confidence intervals (CI). Time-trend analyses
were illustrated in combined diagrams showing observed and pre-
dicted outcomes over time, point-wise impact of the RV vaccine
and the cumulative impact over the time period May 2013 to
December 2014. Results are presented for 3 age groups: i.e. chil-
dren younger than 1 year, 2 years and 5 years.
The analyses were performed by means of the R statistical
package with an addition specifically designed for this type of
analysis [10].
Ethics
The data collected and analysed were anonymised (without per-
sonal identifiers) and no information for individual persons was
evaluated, as only provincial level health statistical data were
used. Individual informed consent is not required for this type
of study, but the provincial health authorities were consulted
about the study procedures and agreed with them.
Results
Incidence of all-cause AGE
Figure 1 presents the number of all-cause AGE cases per 4-week
period in San Luis over the entire study period. A similar figure
for Mendoza may be found in the Supplementary Material avail-
able online for this article (Fig. SM1). In each figure, the vertical
red line marks the respective time points of the start of RV
vaccination.
The boxplot diagram in Figure 2 shows the distribution of the
number of AGE cases per 4-week period in children younger than
5 years old in San Luis for each year, stratified into the age groups
<1 year, <2 years and <5 years. No trends were discernible over
the years before 2013, but for 2014 and onwards the medians
were below the medians observed before 2013.
Time-trend analysis for AGE cases in San Luis (2008–2016)
The results summarised in the upper part of Table 1 indicate
a statistically significant relative reduction of 19% (95% CI
Table 1. Time-trend analysis of AGE cases per 4-week period in San Luis with and without adjustment using Mendoza data as control
Average number of cases
pre-vaccination
Average number of cases
post-vaccination
Predicted number of cases
without vaccination (95% CI)
Absolute effect averted
# of cases (95% CI)
Relative effect
(95% CI) P value
Age
group
Model 1: Time-trend analysis for San Luis (2008–2016)
<1 year








591 475 587 (508–667) −112 (−191 to −33) −19%
(−33% to −6%)
0.003
Model 2: Time-trend analysis for San Luis adjusted by Mendoza as control (2008–2014)
<1 year








591 508 636 (540–735) −127 (−32 to −227) −20%
(−5% to −36%)
0.006
#: Number; CI: confidence interval; AGE: acute gastroenteritis.
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Fig. 3. Time-trend analysis for AGE cases in different age groups
in San Luis, after adjusting with Mendoza data as control group.
This figure shows the number of cases or HDs for the different
age groups by epidemiological week (starting in January
2008). The upper graph (original) contains the observed values
(full line) and the model predicted values in the case of no inter-
vention (dotted line). The middle (pointwise) graph shows the
difference between the observed and predicted value by period
under analysis and the lower (cumulative) graph shows the
cumulative difference throughout the period under analysis.
The vertical dotted line represents the time of introduction of
the vaccine (May 2013). The areas shadowed in light blue refer
to the 95% CI of the estimate in the upper graph (original), of
the difference for each time point (pointwise) in the middle
graph and of the cumulative difference in the lower graph
(cumulative). AGE: acute gastroenteritis.
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6%–33%) of all-AGE cases in children younger than 5 years with
slightly higher relative reductions in the two youngest age groups.
The cumulative number of cases averted in children aged less
than 1, 2 and 5 years until the end of 2016 were 1636 (95%
CI 684–2587), 3698 (95% CI 1489–5895) and 5381 (95%
CI 1573–9183), respectively (Figs SM2 and 3). Regarding the
cumulative number of cases averted and the relative reduction
in the 1 < 2 and 2 < 5 groups were 2063 (95% CI 786–3469)
cases averted and 21% reduction (95% CI 8%–36%) for the
1 < 2 and 1689 (95% CI 19–3473) cases averted and 14%
reduction (95% CI 0%–29%) respectively.
Time-trend analysis of AGE cases in San Luis adjusting with
Mendoza data as control (2008–2014)
These results summarised in the lower part of Table 1 show a stat-
istically significant relative reduction of 20% (95% CI 5%–36%) of
all-cause AGE cases in children younger than 5 years with similar
relative reductions for the two youngest groups. Regarding the
cumulative number of cases averted and the relative reduction
in the 1 < 2 and 2 < 5 groups were 927 (95% CI 185–1659)
cases averted and 20% reduction (95% CI 4%–35%) for the 1 <
2 and 1486 (95% CI 466–2454) cases averted and 24% reduction
(95% CI 7%–39%) respectively.
Figure 3 illustrates the time-trend analysis of all-cause AGE
cases for San Luis (from January 2008 until the end of 2014)
using Mendoza data as control. For each age group, the top
panel shows the observed (full line) and predicted (dotted line)
number of AGE cases; the middle panel shows the time-point
difference between observed and predicted AGE cases and the
bottom panel shows the cumulative difference between the
observed and predicted AGE cases after the start of RV vaccin-
ation until the end of 2014. The cumulative number of cases
averted in children aged less than 1, 2 and 5 years were 583
(95% CI 84–1074), 1527 (95% CI 310–2697) and 2804 (95% CI
695–4990), respectively.
AGE-associated hospitalisations
Figure 4 presents the monthly number of AGE-associated HDs
for the different age groups in San Luis from January 2008 to
the end of 2015. A similar graph for Mendoza is presented in
Figure SM4. In each graph, the vertical red line indicates the
respective start dates of RV vaccination. The boxplot diagram in
Figure 5 shows the distribution per year of the monthly number
of AGE-associated hospitalisations in San Luis. A falling trend
over the period from 2008 to 2012 is discernible in each age
group.
Time-trend analysis for AGE-associated HD in San Luis (2008–
2015)
The results summarised in the upper panel of Table 2 show a rela-
tive reduction in the number of AGE hospitalisations of children
aged <5 years of 56% (95% CI 40%–74%) and slightly higher rela-
tive reductions for the two youngest groups. The cumulative
Fig. 4. Number of AGE-associated HDs per calendar month for different age groups in San Luis.
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number of AGE-associated HDs averted until the end of 2015 in
children aged less than 1, 2 and 5 years were 237 (95% CI 146–
339), 448 (95% CI 276–615) and 603 (95% CI 428–808),
respectively.
Regarding the cumulative number of cases averted and the
relative reduction in the 1 < 2 and 2 < 5 groups were 210 (95%
CI 121–302) cases averted and 56% reduction (95% CI 32%–
81%) for the 1 < 2 and 155 (95% CI 98–214) cases averted and
51% reduction (95% CI 32%–71%) respectively.
Time-trend analysis for AGE-associated HD in San Luis using
Mendoza data as control (2008–2014)
With the prediction model adjusted by Mendoza data as a control,
the average monthly number of AGE-associated hospitalisations
for children aged <5 years was estimated to be reduced by 20
HDs or a statistically significant relative reduction of 54% (95%
CI 38–72) with slightly higher relative reductions for the two
youngest age groups (Table 2, lower part).
Figure 6 shows the time-trend analysis for AGE-related HD for
San Luis (until the end of 2014), using Mendoza data as control.
For each age group, the top panel shows the observed (full line)
and predicted (dotted line) number of AGE-associated HDs; the
middle panel shows for each time point the difference between
the number of observed and predicted AGE-related HDs
and the bottom panel shows the cumulative number of
AGE-associated HDs averted from vaccine introduction until
the end of 2014. For children aged less than 1, 2 and 5 years,
the cumulative number of AGE-associated HDs averted were
Fig. 5. Boxplot of the distribution of the number of AGE-associated HDs per month each year of the study period in children in different age groups in San Luis. AGE,
acute gastroenteritis.
Epidemiology and Infection 7
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268819001936
Downloaded from https://www.cambridge.org/core. IP address: 201.212.68.180, on 28 Nov 2019 at 19:24:50, subject to the Cambridge Core terms of use, available at
165 (95% CI 103–223), 297 (95% CI 184–415) and 399 (95% CI
277–528), respectively.
Regarding the cumulative number of cases averted and the
relative reduction in the 1 < 2 and 2 < 5 groups were 132 (95%
CI 76–189) cases averted and 51% reduction (95% CI 29%–
74%) for the 1 < 2 and 107 (95% CI 71–145) cases averted and
52% reduction (95% CI 34%–70%) respectively.
Direct healthcare costs avoided
Assuming direct healthcare costs of 155 Argentine pesos per AGE
case and 10 340 Argentine pesos per AGE-associated hospitalisa-
tion, the estimated cumulative 2804 AGE cases and 399
AGE-associated hospitalisations averted in San Luis from May
2013 until the end of 2014 would have led to a reduction of direct
healthcare costs of 4 560 280 Argentine pesos (corresponding to
US$ 524 170 using 2014 exchange rate from the World Bank).
Discussion
The observed results in San Luis province regarding the impact of
RV vaccination with and without adjustment by data from
Mendoza resulted in quite similar estimates. Figure 7 presents a
summary of the outcomes and the impact of this study for health-
care providers. The impacts observed were relative reductions of
∼20% in the number of all-cause AGE cases and of 55–60% in
the number of AGE hospitalisations. There was a tendency that
the impact was a little greater for infants aged <1 year than for
the older age groups. The associated reduction in direct medical
costs of outpatient care and hospitalisations amounted to more
than 4.5 million Argentine pesos in San Luis over the period
from May 2013 to the end of 2014.
Previous ecological studies of the impact of RV vaccination in
Latin American countries have generally focused on all-cause
AGE-related mortality and hospitalisations because data on
laboratory-confirmed RV-positive cases are normally not available
at the population level. Early studies from four countries (Brazil, El
Salvador, Mexico and Panama) reported reductions of all-cause
AGE hospitalisations ranging between 17% and 51% in children
aged <5 years [14–18]. A few studies with RV-specific data avail-
able reported reductions of RVGE hospitalisations ranging from
59% to 81% in <5-year-olds [19, 20]. Large reductions in mortality
of severe diarrhea have also been reported [14, 15, 21].
Newer studies tend to report more limited impact.
Combining data from four countries (Bolivia, El Salvador,
Honduras and Venezuela), De Oliveira et al., reported reduc-
tions in all-cause AGE hospitalisations of 12.4% in children
aged <1 year and 8.5% in children aged <5 years. The range
across countries was 7.5–27.0% for the 0- to 1-year-olds and
5.6–17.9% for the 0- to 5-year-olds [22]. A renewed analysis in
Brazil with data for at least 5 years after RV vaccine introduction
showed a sustained reduction in all-cause AGE hospitalisations
of 31% in children aged <1 year and 22.4% in children aged
1–4 years [23].
Although the point estimates of the reduction in all-cause
AGE hospitalisations vary widely between these disease-burden
trend analyses, they are consistent in estimating a statistically sig-
nificant impact. Our results are in line with this but with larger
estimated reductions in all-cause AGE hospitalisations than in
the previous studies. No other study of the impact of RV vaccin-
ation on the overall number of all-cause AGE cases in Latin
America has been identified.
RVGE in infants is often more severe than AGE of other
causes. Thus, it has been estimated that the proportions of
RVGE cases among all-cause AGE cases are 5–10% for cases
taken care of by the child’s parents or caretakers in the home,
15–20% of cases presenting in primary care or outpatient settings
and 30–50% of hospitalised cases [24]. The proportions found in
Argentina correspond to this, with RVGE accounting for 17% of
all AGE cases [7] and 42% of hospitalised AGE cases [8]. That the
estimated relative reduction in AGE outcomes is approximately
three times higher for all-cause AGE-related hospitalisations
than for the overall number of AGE cases presenting for medical
care is therefore suggestive of an effect of RV vaccination.
Our assumption that the reduction in all-cause AGE cases and
hospitalisations could be attributed to RV vaccination is sup-
ported by the lack of evidence on any changes in the registration
of AGE cases during the study period. Its robustness was further-
more tested by randomly selecting five hypothetical time points
for the introduction of RV vaccination in San Luis and testing
the statistical prediction models based on these sham intervention
time points. These tests showed no significant deviation between
the predicted and observed outcomes and this was taken to
support the robustness of the assumption and the model.
Previous RV-vaccination impact studies generally make similar
assumptions.









# of HD (95% CI)
Relative effect observed
(95% CI) P ValueAge group
Model 1: Time-trend analysis for San Luis (2008–2015)
<1 year 12 5 12 (10–16) −7 (−5 to −11) −60% (−37% to −86%) 0.001
<2 years 22 10 24 (19–29) −14 (−9 to −19) −58% (−36% to −80%) 0.001
<5 years 32 15 34 (28–40) −19 (−13 to −25) −56% (−40% to −74%) 0.001
Model 2: Time-trend analysis for San Luis adjusted by Mendoza as control (2008–2014)
<1 year 12 6 14 (11–17) −8 (−5 to −11) −59% (−37% to −80%) 0.001
<2 years 22 12 27 (21–33) −15 (−9 to −21) −55% (−34% to −77%) 0.001
<5 years 31 17 37 (31–43) −20 (−14 to −26) −54% (−38% to −72%) 0.001
HD, Hospital discharges; CI, confidence interval; #, Number; AGE, acute gastroenteritis.
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In a recent systematic review and meta-analysis of case-
control studies of the effectiveness of RV vaccination in Latin
America, Santos et al. found that RVGE amounted to 24%
and 16% of all AGE cases before and after the introduction of
RV vaccination, respectively. Their estimates of vaccination
effectiveness were 53% against RV infection, 74% against severe
RVGE and 73% against RVGE hospitalisations [5]. It seems rea-
sonable to expect that these RVGE-specific estimates of the
effectiveness of RV vaccination should be broadly applicable to
Argentina also.
Fig. 6. Time-trend analysis for AGE-associated HDs in San Luis for
children in different age groups, after adjusting with Mendoza
data as the control group. This figure shows the number of
cases or HDs for the different age groups by epidemiological
week (starting in January 2008). The upper graph (original) con-
tains the observed values (full line) and the model predicted
values in the case of no intervention (dotted line). The middle
(pointwise) graph shows the difference between the observed
and predicted value by period under analysis and the lower
(cumulative) graph shows the cumulative difference throughout
the period under analysis. The vertical dotted line represents
the time of the introduction of the vaccine (May 2013). The
areas shadowed in light blue refer to the 95% CI of the estimate
in the upper graph (original), of the difference for each time point
(pointwise) in the middle graph and of the cumulative difference
in the lower graph (cumulative). AGE: acute gastroenteritis.
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A self-evident limitation of our study is that all-cause AGE
was used as the outcome, so it is not possible to obtain a
RVGE-specific estimate of the impact of the RV vaccine.
However, it may arguably be the case that estimating the impact
on all-cause AGE is more valuable for decision making in provid-
ing an estimate of the fraction of AGE outpatient cases and hos-
pitalisations preventable by RV vaccination.
Even if RVGE cases were identified, the ecological study design
precludes definitive conclusions about the impact of RV vaccin-
ation, because such studies do not link an outcome to an exposure
at the individual level. Herd effects with indirect protection of
unvaccinated children complicate the assessment of a causal asso-
ciation between vaccination coverage and disease patterns. That we
found almost the same relative reduction for the age group <5 years
as for the two youngest groups may suggest that herd protection
occurred because a large proportion of the children in the <5
years group were too old to be vaccinated in the setting of the pro-
vincial vaccination program. Herd effects have been observed in
many studies after the introduction of general RV vaccination
with a range of effects from 0 to 72%, varying considerably between
consecutive years; generally, the estimated effect diminishes with
increasing age of the children (studies cited in [25]).
With only 1.5 years of observation post vaccination this impact
study is provisional and to assess the medium- to long-term
impact of RV vaccination with possible serotype replacement or
changes in seasonality or the disease profile, continued surveil-
lance at the national level is required. The almost complete cover-
age obtained in San Luis may be a cause of the high impact, the
2-dose coverage observed in Argentina after the introduction of
RV vaccination in the national vaccination program in January
2015 is much lower (85% in 2015 and 74% in 2016).
Conclusions
Similar to the findings of many other studies of the early impact
of RV vaccination we found a higher effect of RV vaccination in
preventing more severe AGE cases requiring hospitalisation than
in preventing all cases of AGE presenting for medical care. We
also showed that RV vaccination led to substantial immediate sav-
ings of direct medical costs in the San Luis province.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268819001936
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